Testing effectiveness (Phase 2)Study completedNCT01744691
What this trial is testing
Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion
Who this might be right for
Chronic Lymphocytic Leukemia With 17p DeletionSmall Lymphocytic Lymphoma With 17p Deletion
Pharmacyclics LLC. 145